A review of the clinical literature on combining GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide, and related agents) with running or endurance training.

The honest starting point

There is no large clinical trial of GLP-1 receptor agonists conducted specifically in runners. Almost everything known about this combination comes from obesity trials that included a generic exercise arm — usually supervised cycling, circuit training, or “moderate-to-vigorous physical activity” rather than running — plus a small number of case reports, cohort surveys of recreational exercisers, and mechanistic studies of heart rate and gut physiology. That’s a real limitation, and any claim about “runners on Ozempic” that isn’t traceable to one of those sources is opinion, not evidence. With that caveat, several findings are well established enough to build practical guidance on.

The best available trial: exercise and liraglutide together

The most rigorous data come from the Danish S-LiTE trial (Lundgren et al., NEJM 2021), a randomized, placebo-controlled study of 195 adults with obesity. After an 8-week low-calorie diet, participants were assigned for one year to one of four arms: exercise alone, liraglutide alone, exercise plus liraglutide, or placebo. The exercise program targeted WHO physical-activity guidelines using a mix of interval cycling, circuit training, and individual aerobic sessions (commonly running, cycling, or brisk walking).

A 2026 secondary analysis of this trial (Jensen et al., Sports Medicine) looked specifically at physical fitness outcomes — cardiorespiratory fitness (peak oxygen consumption), stair-climb performance, and muscle strength. The results are the single most informative data point available for anyone stacking a GLP-1 drug on top of a training plan:

The takeaway the authors state directly: weight loss from a GLP-1 drug does not, by itself, translate into better fitness. Fitness gains came from the exercise, not the injection. A related earlier finding from the same trial cohort showed that only the combined exercise-plus-liraglutide group saw meaningful improvements in glucose tolerance and beta-cell function — another marker that pairing the drug with structured training, rather than using it alone, is where the physiological benefit concentrates.

A separate RCT combining exercise with a GLP-1 agonist (Jabbour et al., Cardiovascular Diabetology 2023) similarly found that adding structured exercise to GLP-1 therapy produced greater reductions in metabolic syndrome severity, abdominal obesity, and inflammatory markers than the drug alone.

Lean mass loss: the central concern for runners

Across GLP-1 and dual GLP-1/GIP trials, roughly 25–40% of total weight lost is lean (fat-free) tissue rather than fat, based on DXA substudies:

This matters for runners specifically because running economy, injury resistance, and bone loading all depend partly on muscle mass and strength, not just body weight. Losing muscle alongside fat can flatter body weight and body-fat percentage on paper while leaving strength, tendon resilience, and power output worse off — the “skinny fat” concern clinicians have started raising.

Two caveats temper the alarm somewhat. First, lean soft tissue on DXA includes water, connective tissue, and organ mass, not just contractile muscle — so the percentages above overstate true skeletal muscle loss. Second, a small 2025 case series (Tinsley & Nadolsky) described three patients on semaglutide or tirzepatide who deliberately combined the drug with resistance training 3–5 days/week and higher protein intake; their lean tissue changes ranged from a 6.9% loss up to a 5.8% gain, alongside large fat losses. It’s a case series, not a trial, but it’s consistent with a broader, better-supported pattern: resistance exercise and adequate protein intake blunt lean mass loss during GLP-1 therapy, while aerobic exercise alone is a weaker countermeasure for muscle specifically (this mirrors what’s known about calorie-restriction-only weight loss as well). A registered trial (the Exeter “FLEX” study, and a separate Stage 1 Registered Report on musculoskeletal preservation) is underway to test this more rigorously, with results expected over the next couple of years.

Practical implication for a runner: running mileage alone is unlikely to fully protect muscle while on a GLP-1 drug. The literature points toward adding resistance training and prioritizing protein intake, not just logging more easy miles.

Does a GLP-1 drug make you a better or worse runner?

No published human study shows GLP-1 receptor agonists directly improving endurance performance, VO2max, or running economy. If anything, the S-LiTE fitness data above suggest the opposite risk: weight loss without a training stimulus does not automatically raise fitness, and rapid loss of lean mass could plausibly impair running economy and strength if training doesn’t keep pace. There are no controlled trials measuring race times, running economy, or VO2max changes in trained runners or endurance athletes using these drugs — this is a genuine research gap, and most of what circulates online (dietitian and coaching blogs, anecdote-driven articles) is extrapolation, not primary data.

Two regulatory/physiological notes worth flagging:

Practical safety issues that matter mid-run

The GI mechanism of these drugs (delayed gastric emptying, reduced appetite) creates specific frictions with endurance training that are documented in safety literature and consistently echoed by sports dietitians, even though sport-specific trial data is thin:

A signal worth naming carefully: mental health and disordered eating

A 2025 survey study of recreational exercisers and athletes found that those who had used or considered using GLP-1 drugs reported clinically elevated anxiety, depression, and body-image disturbance more often than non-users, with a stronger pattern in women. This is a cross-sectional, self-selected sample — it shows association, not causation, and can’t distinguish “the drug caused distress” from “people with more body-image concern were more likely to seek out the drug.” It’s included here because exercise populations (especially endurance athletes) already carry elevated baseline rates of disordered eating, and clinicians and coaches working with runners on these medications should have that risk on their radar rather than assuming a purely mechanical, appetite-only effect.

Bottom line

The clinical picture, as far as it currently extends: GLP-1 receptor agonists reliably produce weight and fat loss, but that weight loss does not by itself improve cardiorespiratory fitness or running-relevant strength — those gains still depend on structured training, per the best-controlled trial available (S-LiTE). Somewhere between a quarter and 40% of weight lost on these drugs is lean tissue, and resistance training plus adequate protein — not aerobic volume alone — is the intervention with the best (if still limited) evidence for protecting muscle. No study has measured direct performance effects (VO2max, running economy, race times) in trained runners, so anyone claiming an ergogenic or ergolytic effect is going beyond the data. The more immediate, better-documented issues for runners are practical: GI tolerance of pre-run fueling, hydration, a small resting-heart-rate shift relevant to HR-based training, and — in people combining these drugs with insulin or sulfonylureas — hypoglycemia risk.

This is a fast-moving literature with real gaps (no dedicated endurance-athlete RCTs yet, though a few are registered and underway). This piece reflects the published evidence as of mid-2026 and isn’t a substitute for individualized medical advice — anyone on or considering a GLP-1 drug while training seriously should loop in the prescribing clinician, ideally one who understands endurance sport.

Sources